Systemic Aspergillosis: Radiological Findings in a Case With Diffuse Large B Cell Lymphoma Treated by Ibrutinib

Umur Anil Pehlivan 1, Hasan Bilen Onan 2, Ertugrul Bayram 3, Celalet Keser 4, Semra Paydas 3

1. Radiology, Van Baskale State Hospital, Van, TUR 2. Radiology, Çukurova University Faculty of Medicine, Adana, TUR 3. Medical Oncology, Çukurova University Faculty of Medicine, Adana, TUR 4. Anesthesiology and Reanimation, Çukurova University Faculty of Medicine, Adana, TUR

Corresponding author: Umur Anil Pehlivan, uapehlivan@gmail.com

Abstract

Herein, we present a case of systemic aspergillosis with a fatal outcome in a case with diffuse large B cell lymphoma (DLBCL) treated by ibrutinib. Aspergillosis was suspected clinically and proven microbiologically. Radiological findings were compatible with aspergillosis. We aim to review radiological findings in a case with DLBCL treated with ibrutinib, which is an important tyrosine kinase inhibitor used in lymphoid neoplasias.

Categories: Radiology, Infectious Disease, Oncology

Keywords: adverse event, chest imaging, neuroimaging, systemic aspergillosis, ibrutinib, diffuse large b-cell lymphoma

Introduction

Ibrutinib is a potent inhibitor of Bruton’s tyrosine kinase (BTK), and therefore, it offers a long-term survival advantage when used for the treatment of B-cell malignancies [1]. However, some case reports have identified side-effects associated with ibrutinib therapy, including systemic fungal infections [2-4]. Aspergillosis is a mycotic infection caused by Aspergillus fumigatus that mainly affects the pulmonary system [5]. In immunocompromised patients, Aspergillus may cause systemic, invasive, life-threatening complications in the presence of fungemia. Aspergillosis presents with specific radiological findings, but not in all cases [5,6]. Early diagnosis and treatment are crucial for immunocompromised patients because otherwise, the infection rapidly progresses, and irreversible/catastrophic events occur with poor outcomes.

Case Presentation

In March 2014, an 80-year-old male presented with resistant diffuse large B-cell lymphoma (DLBCL; activated B-cell type). The patient was treated with rituximab-mini CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone). In May 2019, the patient relapsed and was treated with R-bendamustine and lenalidomide. In March 2020, the patient relapsed again and was treated with ibrutinib. Initially, no significant toxicity developed, although the patient suffered muscle pains. However, after three months of ibrutinib treatment, the disease progressed. After progression, venetoclax was started at 20 mg/day with a ramp-up schedule while ibrutinib was continuing. However, one week later, Babinski positivity, tachycardia, arrhythmia, respiratory distress, and disorientation developed. Non-contrast cerebral computed tomography (CT) showed a hypodense nodular lesion with edema in the right frontal region (Figure 1). First, cerebral lymphoma involvement was suspected; however, magnetic resonance imaging (MRI) with conventional and perfusion imaging showed bilateral nodular lesions with edema around the lesion, peripherally restricted diffusion, and peripheral enhancement. These lesions were hypoperfused in perfusion-weighted images (Figure 2). All these radiologic findings were compatible with opportunistic infections. Bilateral patchy ground-glass opacities, consolidation, and left pleural effusion were observed on thorax CT (Figure 3). These radiologic images were compatible with opportunistic lung infection. A serum Aspergillus antigen (galactomannan) test was positive. When the diagnosis of aspergillosis was microbiologically proven, neutropenia was not detected. Then, amphotericin B and meropenem were started. However, three days later, multisystem organ failure developed. Hemodialfiltration for acute renal failure and intravenous immunoglobulin for hypogammaglobulinemia was administered; despite these interventions, the patient died on the eighth day.
FIGURE 1: Hypodense nodular lesion with edema in right frontal region is present in non-contrast enhanced computed tomography.
FIGURE 2: Bilateral nodular lesions with edema around the lesion (a), peripheral restricted diffusion (b), and peripheral enhancement (c, d), were observed. These lesions were hypoperfused in perfusion-weighted images (e).
FIGURE 3: Bilateral patchy ground-glass opacities and consolidation were observed in thorax computed tomography.

Discussion

Ibrutinib is a BTK inhibitor for B-cell malignancies. However, it may cause invasive fungal infections within the first three months of therapy [7]. In the present case, the pathogenesis of the invasive fungal infection was related to the immunodeficiency due to lymphoma, ibrutinib use, and probably lenalidomide use in previous treatment. The pathogenesis of opportunistic infections due to ibrutinib use is associated with macrophage dysfunction and degradation of the BTK/nuclear factor kappa-B pathway, which may be fatal [8]. Invasive fungal infections of the central nervous system (CNS) occur with hematogenous spreading, cerebrospinal fluid seeding, and adjacent invasion [6]. Aspergillosis accounts for most invasive fungal infections, as in our case. Pulmonary aspergillosis includes five subtypes: aspergilloma, bronchopulmonary aspergillosis, semi-invasive aspergillosis, airway invasive aspergillosis, and angio-invasive aspergillosis [5,9]. Pulmonary manifestations of invasive aspergillosis are due to the invasion of vessels and airways by A. fumigatus in immunocompromised patients, as in the present case [5,9]. Multisystemic aspergillosis associated with ibrutinib use may cause catastrophic outcomes. Therefore, the early detection of pathogenic agents is important. Laboratory tests including blood, phlegm, and bronchoalveolar lavage are not always diagnostic. Galactomannan is the only polysaccharide antigen characterized in A. fumigatus, and it is useful for the diagnosis of aspergillosis in patients with hematological malignancy [9]. In addition, the radiological features of invasive fungal infections are often nonspecific, but some imaging findings may be diagnostic [5,6]. Therefore, thin-section CT and cerebral MRI should be used for early detection of findings compatible with invasive fungal infections in immunocompromised patients [6,10]. Pulmonary manifestations of invasive aspergillosis can be identified by thin-section CT with specific but non-pathognomonic findings [5,6]. Pulmonary manifestations of invasive aspergillosis are identified by thin-section CT as a tree in bud, ground-glass opacity or pleural-based, wedge-shaped areas of consolidation, peribronchial and lobar consolidation, bronchial dilatation, mucoid impaction, or post-obstructive atelectasis [5]. The MRI features of CNS aspergillosis include perilesional edema, heterogeneous or ring-reduced diffusion, and weak-ring enhancement, as in our case [6]. Some cases of angioinvasive aspergillosis present with multifocal hemorrhagic lesions or stroke [6]. It is also important to know the specific radiological findings of other pathogens involved in the differential diagnosis of aspergillosis [6]. For example, cryptococcus is characterized by the gelatinous transformation in the basal ganglia. Mucormycosis shows restricted diffusion in the frontal lobe. Candidiasis is characterized by microabscesses at the corticomedullary
junction, basal ganglia, and cerebellum. Blastomycosis and histoplasmosis present with parenchymal abscesses and meningitis [6]. In addition to conventional MRI, perfusion-weighted MRI can be useful for the differential diagnosis of space-occupying lesions.

Conclusions

In conclusion, clinicians should be careful when dealing with invasive fungal infections in cases treated by ibrutinib, and treatment must be started as soon as possible to prevent fatal outcomes. Radiologic findings are helpful to detect opportunistic infections in cases treated by ibrutinib. This case report has been presented as an E-Poster at the 46th Turkish National Haematology Congress - October 28-31, 2020.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Novero A, Ravella PM, Chen Y, Dous G, Liu D: Ibrutinib for B cell malignancies. Exp Hematol Oncol. 2014, 3:4. 10.1186/2162-3619-3-4
2. Chamilos G, Lionakis MS, Kontoyiannis DP: Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis. 2018, 66:140-8. 10.1093/cid/cix037
3. Zarakas MA, Desai JV, Chamilos G, Lionakis SM: Fungal infections with ibrutinib and other small-molecule kinase inhibitors. Curr Fungal Infect Rep. 2019, 15:86-98. 10.1007/s12281-019-00343-9
4. McCarter SJ, Vijayvargiya P, Sidana S, et al.: A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. Leuk Lymph. 2019, 60:559-61. 10.1080/10428194.2018.1494271
5. Franques T, Müller LN, Giménez A, Guembe P, de La Torre I, Bagué S: Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. RadioGraphics. 2001, 21:825-37. 10.1148/radiographics.21.4.g01jl03825
6. Starkey J, Moritani T, Kirby P: MRI of CNS fungal infections: review of aspergillosis to histoplasmosis and everything in between. Clin Neuroradiol. 2014, 24:217-30. 10.1007/s00062-014-0505-7
7. Ghez D, Calleja A, Protin C, et al.: Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018, 131:1955-9. 10.1182/blood-2017-11-818286
8. Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ: Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma. 2020, 61:2488-91. 10.1080/10428194.2020.1775215
9. Davda S, Kowa XY, Aziz Z, Ellis S, Cheasty E, Cappocci S, Balan A: The development of pulmonary aspergillosis and its histologic, clinical, and radiologic manifestations. Clin Radiol. 2018, 73:913-21. 10.1016/j.crad.2018.06.017
10. Hensel CP, Kauczor HU, Heussel G, Fischer B, Mildemberger P, Thelen M: Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. Am J Roentgen. 1997, 169:1347-53. 10.2214/ajr.169.5.9553456